Implementing WHO recommendations for NGS in Drug-Resistant Tuberculosis (DR-TB) can seem like a complex journey. Looking for clarity and a clear path forward?

This webinar is part of a six-part webinar series which provides a practical roadmap and real-world guidance by showcasing the implementation journeys of pioneering national TB programs integrating targeted NGS into their TB testing algorithms. In this webinar, Mexico - in the embedding phase, will share their experience of pioneering their national TB program.

This focused 30-minute webinar delivers specific stories and lessons learned aligned with these implementation stages, offering a comprehensive understanding of the process and the tangible impact of NGS on DR-TB control.

Gain practical insights to accelerate your End TB goals by learning directly from the pioneering experts leading this transformative change. Ready to translate WHO recommendations into actionable strategies? Register now for the whole six-part webinar series.

In this series, you will discover:

• The key drivers and infrastructure considerations for adopting tNGS in diverse national settings.
• Understanding of national models for NGS-enhanced TB testing algorithms.
• Real-world impact and best practices for successful tNGS implementation.

Speaker:

Dr Luis Narváez Díaz Clinical Microbiologist and Adjunct Professor Infectology specialty at the National Institute of Respiratory Diseases (INER) Dr Luis Narváez Díaz is an experienced medical professional dedicated to capacity building and training of human resources in the field of infectious diseases. He serves as an adjunct professor in the high-specialty residency program for drug-resistant tuberculosis, as well as in the microbiology department within the Infectology specialty at the National Institute of Respiratory Diseases (INER). His research contributions at INER include participation in protocols focused on the sequencing of mycobacteria to identify genetic markers of drug resistance, and the development of a comprehensive model integrating clinical data, pulmonary microbiota, and immune response in both latent and active tuberculosis. He has also been involved in studies evaluating four-drug oral short-term treatments for rifampicin- and multidrug-resistant tuberculosis (RR/MDR-TB) in Mexico, investigations into risk factors for isoniazid-monoresistant TB, clinical diagnosis of mycobacteriosis, and the surveillance and diagnosis of latent TB in healthcare workers.